Company Introduction

Company introduction

3) Indication: Prevention of influenza for persons above 6 months

IL-YANG 4) ‌Development stage:
- WHO Prequalification submitted on JAN, 2015
PHARMACEUTICAL CO., LTD. - BLA approval on 8th AUG, 2013 in Republic of KOREA
5) Key features
- The IL-YANG Inactivated Split Influenza Vaccine showed HI antibody met the US FDA guideline
for both age groups, the 6 month to < 18 year age group (Children) and the ≥ 18 year age group
(Adults)
Respect Humanity, Promote Human’s Health, - The long-term safety assessments showed low frequency serious adverse events
Improve Welfare
R&D Pilpeline
IL-YANG Pharmaceutical Co., Ltd. has been exerting its intended
efforts to manufacture superior pharmaceutical products for the last
half a century and it is still going on. Since it took the first step to
supply pharmaceutical products in Korea, since 1946, IL-YANG has
been advancing into a top-ranking pharmaceutical company in the
world with developing in the area of Gastrointestinal, Hematology,
Vaccine, and Virology. IL-YANG established vaccine plant in April 2011
with production capacity of 60mil doses per year. IL-YANG has been
exporting a variety of pharmaceuticals to approximately 30 countries
including USA and Europe. IL-YANG established two branches in
China, YANGZHOU IL-YANG PHARM. Co., Ltd. and TONGHUA IL-YANG
HEALTH PRODUCTS Co., Ltd. for manufacturing and distribution of
finished pharmaceuticals in China. Since their establishment, the sales
and business are expanding enormously. In Sept. 2014, YANGZHOU IL-
YANG had completion ceremony for newly built cGMP plant which is
compliance to EU-GMP standard.

Products
IL-Yang Flu Vaccine INJ.
1) ‌Purified inactivated trivalent influenza split vaccine (Vial & Prefilled
CEO syringe)
DONG YEON, KIM 2) Thimerosal-free & preservative-free product (fertilized embryo based)
Location
IL-YANG BLDG. 194 Dogok-ro,
Gangnam-gu, Seoul, Korea
Homepage
www.ilyang.co.kr

38 39